Home・Listă Acțiuni・Krystal Biotech Inc

Krystal Biotech Inc

Închisă

SectorSănătate

322.67 0.03

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

319.45

Maxim

327.74

Indicatori cheie
By Trading Economics
Venit	-1.2M 55M
Vânzări	2.9M 119M
P/E Medie Sector	45.697 68.51
EPS	1.79
Marjă de profit	45.938
Angajați	295
EBITDA	2.9M 66M

Recomandări
By TipRanks
Recomandări	Puternic Cumpărare
Prognoză pe 12 luni	+23.76% upside

Dividende
By Acuity
Următoarele câștiguri	2 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	-1.1B 9.3B
Deschiderea anterioară	322.64
Închiderea anterioară	322.67

Sentimentul știrilor

By Acuity

86%

14%

323 / 340 Clasament în Healthcare

Krystal Biotech Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

5 aug. 2026, 19:52 UTC

Krystal Biotech Inc shares are lower today, breaking a trend of higher closes. Broader market sentiment is cautious following ADP's weak employment report.

4 aug. 2026, 20:04 UTC

News

Citigroup raised its price target on Krystal Biotech to $386, contributing to upward movement in shares despite earlier session pullbacks.

3 aug. 2026, 23:06 UTC

Krystal Biotech Inc shares are higher in after-market hours, recovering from an earlier dip. Broader market sentiment improved following stronger-than-expected economic data.

31 iul. 2026, 23:06 UTC

Krystal Biotech Inc is trading lower in after-market hours amid volatility, with no specific news identified to explain the movement.

30 iul. 2026, 19:39 UTC

Krystal Biotech Inc shares are higher today, maintaining gains since Wednesday's close. The stock remains above its 20-day moving average despite a slight pullback.

29 iul. 2026, 20:04 UTC

Krystal Biotech shares are lower amid a broader market decline, influenced by significant drops in major U.S. stocks ahead of the Federal Reserve's announcement.

28 iul. 2026, 20:03 UTC

Event

Social Media

Krystal Biotech Inc. shares rise amid strong Biotechnology sector gains and positive social media discussions, with Q2 FY2026 earnings expected on August 3.

27 iul. 2026, 22:02 UTC

Social Media

Shares of Krystal Biotech are lower in after-market hours, despite discussions of potential catalysts and an upcoming earnings report on August 3.

24 iul. 2026, 19:11 UTC

Krystal Biotech Inc shares are higher today, despite broader market weakness. The stock has seen increased trading activity since Thursday's close.

23 iul. 2026, 10:01 UTC

Krystal Biotech Inc shares are higher in pre-market hours, following a slight after-market increase on Wednesday. No specific news was identified for this movement.

22 iul. 2026, 19:26 UTC

Krystal Biotech Inc shares are lower today amid a broader market decline, with no specific company news identified to explain the movement.

21 iul. 2026, 18:36 UTC

News

Social Media

Krystal Biotech Inc shares are lower today amid trading volatility, despite a planned inclusion in the S&P MidCap 400 on July 24.

20 iul. 2026, 21:21 UTC

News

Krystal Biotech Inc. will replace Taylor Morrison in the S&P MidCap 400 on July 24, 2026. The stock is lower in after-hours trading.

Comparație

Modificare preț

Krystal Biotech Inc Așteptări

Obiectiv de preț

By TipRanks

23.76% sus

Prognoză pe 12 luni

Medie 403.2 USD 23.76%

Maxim 474 USD

Minim 361 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruKrystal Biotech Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Puternic Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Krystal Biotech Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

323 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Krystal Biotech Inc

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.